Korro receives european medicines agency orphan drug designation for krro-110

Cambridge, mass., july 21, 2025 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing rna for both rare and highly prevalent diseases, announced today that it has been granted orphan drug designation by the european medicines agency (ema) committee, who adopted a positive opinion on krro-110, korro's investigational medicine for the treatment of alpha-1 antitrypsin deficiency (aatd).
KRRO Ratings Summary
KRRO Quant Ranking